OKYO Pharma Limited, (OKYO) News
Filter OKYO News Items
OKYO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OKYO News From Around the Web
Below are the latest news stories about OKYO PHARMA LTD that investors may wish to consider to help them evaluate OKYO as an investment opportunity.
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceLONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that its CEO, Gary S. Jacob, Ph.D., will be participating in one on one meetings and a fireside chat at the 4th Annual Virtu |
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma Ltd. (Nasdaq:OKYO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg ... |
OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceLONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it will be presenting at the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy during O |
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainOK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 is the first IND granted by FDA to treat patients with NCP LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neur |
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain DrugOKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain (NCP), a rare and debilitating eye condition lacking FDA-approved treatments. The trial aims to enroll 48 participants and follows promising results from a previous trial where OK-101 showed significant improvements in ocular pain associated with dry eye disease. This development marks a crucial step for OKYO as it con |
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainNeuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 demonstrated statistically significant pain relief in a recently completed Phase 2 trial of dry eye disease LONDON and NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NA |
OKYO Pharma Announces Chairman Acquires SharesLONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entit |
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseLONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key U.S. Patent No. 12,053,501 which issued on Augu |
OKYO Pharma CEO Interview to Air on Bloomberg TVLONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedCh |
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this ... |